Markus Naumann
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Markus Naumann has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
H Hamm
2 shared publications- LÁSzlÓ Solymosi
Dept. of Neuroradiology, University Hospital Würzburg, Würzburg, Germany
2 shared publications A. Yakovleff
Hopital Raymond, Poincaré Service de Rééducation Neurologique, Garches, France FR
1 shared publicationAxel Schramm
Dept. of Neurology, Julius-Maximilians-Universität Würzburg, Würzburg, Germany
1 shared publicationB. Eberhardt
1 shared publicationB. Merz
Dept. of Neurology, University of Würzburg, Würzburg, Germany
1 shared publication
Latest Publications
- 1 October 2004
- Published by Springer Nature in Journal of Neurology
- Vol. 251 (10) , 1270-1272
Parkinsonism due to bilateral basal ganglia lesions following mastocytosis-induced hypoxia
- 1 October 2004
- Published by Springer Nature in Journal of Neurology
- Vol. 251 (10) , 1270-1272
Parkinsonism due to bilateral basal ganglia lesions following mastocytosis-induced hypoxia
- 27 April 2004
- Published by Informa Healthcare in Current Medical Research and Opinion
- Vol. 20 (7) , 981-990
Safety of botulinum toxin type A: a systematic review and meta-analysis
SUMMARYObjective: To define quantitatively the safety and tolerability profile of botulinum toxin type A (BTX-A) across all common therapeutic indications. The review was limited to the evaluation of the safety profile of one preparation of BTX-A (Botox*) because distinct formulations of BTX-A are associated with different clinical profiles, requiring separate consideration for an analysis of safety.Research design and methods: We identified randomized controlled trials of BTX-A through searches of the MEDLINE, EMBASE, and Cochrane Controlled Trial databases for the years 1966–2003. Studies were double-blind, randomized, crossover, or of parallel group design. The search strategy included the terms ‘botulinum toxin’, ‘therapeutic use’, ‘randomized controlled trial’, ‘controlled clinical trial’, ‘randomized clinical trial’, and ‘placebo controlled trial’. Only randomized controlled trials of at least 7 days duration that reported adverse events were included in the analysis.Main outcome measure: Safety was...
- 27 April 2004
- Published by Informa Healthcare in Current Medical Research and Opinion
- Vol. 20 (7) , 981-990
Safety of botulinum toxin type A: a systematic review and meta-analysis
SUMMARYObjective: To define quantitatively the safety and tolerability profile of botulinum toxin type A (BTX-A) across all common therapeutic indications. The review was limited to the evaluation of the safety profile of one preparation of BTX-A (Botox*) because distinct formulations of BTX-A are associated with different clinical profiles, requiring separate consideration for an analysis of safety.Research design and methods: We identified randomized controlled trials of BTX-A through searches of the MEDLINE, EMBASE, and Cochrane Controlled Trial databases for the years 1966–2003. Studies were double-blind, randomized, crossover, or of parallel group design. The search strategy included the terms ‘botulinum toxin’, ‘therapeutic use’, ‘randomized controlled trial’, ‘controlled clinical trial’, ‘randomized clinical trial’, and ‘placebo controlled trial’. Only randomized controlled trials of at least 7 days duration that reported adverse events were included in the analysis.Main outcome measure: Safety was...
- 1 March 2004
- Published by Wiley in Movement Disorders
- Vol. 19 (S8) , S137-S141
Botulinum toxin treatment of secretory disorders
Botulinum neurotoxin serotype A (BoNT/A) has revolutionised the treatment of a variety of autonomic hypersecretory disorders. Several open and controlled studies indicate that BoNT/A is a safe and effective treatment for focal hyperhidrosis of the axillae and palms, for gustatory sweating, and for some other rare conditions associated with focal hyperhidrosis. There is class I evidence for the efficacy of botulinum toxin in axillary hyperhidrosis and class II evidence for palmar hyperhidrosis and gustatory sweating. BoNT/A has the potential to replace current invasive and surgical techniques and should at least be considered as a viable alternative. The results of pilot studies to treat sialorrhea are encouraging. However, the optimal dose, best mode of application, side effects, and duration of BoNT/A action in this condition remain uncertain. We need further formal clinical trials to evaluate risks and benefits of BoNT/A for palliative treatment in of sialorrhea in Parkinson's disease and in bulbar amyotrophic lateral sclerosis. Based on the few reports published, BoNT/A injections into the lacrimal gland for hyperlacrimation may be an elegant method to treat this sometimes disabling condition. Again, larger studies are needed to evaluate the risks and long‐term benefits of this treatment option. © 2004 Movement Disorder Society
- 1 March 2004
- Published by Wiley in Movement Disorders
- Vol. 19 (S8) , S137-S141
Botulinum toxin treatment of secretory disorders
Botulinum neurotoxin serotype A (BoNT/A) has revolutionised the treatment of a variety of autonomic hypersecretory disorders. Several open and controlled studies indicate that BoNT/A is a safe and effective treatment for focal hyperhidrosis of the axillae and palms, for gustatory sweating, and for some other rare conditions associated with focal hyperhidrosis. There is class I evidence for the efficacy of botulinum toxin in axillary hyperhidrosis and class II evidence for palmar hyperhidrosis and gustatory sweating. BoNT/A has the potential to replace current invasive and surgical techniques and should at least be considered as a viable alternative. The results of pilot studies to treat sialorrhea are encouraging. However, the optimal dose, best mode of application, side effects, and duration of BoNT/A action in this condition remain uncertain. We need further formal clinical trials to evaluate risks and benefits of BoNT/A for palliative treatment in of sialorrhea in Parkinson's disease and in bulbar amyotrophic lateral sclerosis. Based on the few reports published, BoNT/A injections into the lacrimal gland for hyperlacrimation may be an elegant method to treat this sometimes disabling condition. Again, larger studies are needed to evaluate the risks and long‐term benefits of this treatment option. © 2004 Movement Disorder Society
- 1 February 2004
- Published by Springer Nature in Der Nervenarzt
- Vol. 75 (2) , 128-134
Differenzierung atypischer Parkinson-Syndrome und ihre Abgrenzung vom idiopathischen Parkinson-Syndrom mit Hilfe der Routine-Magnetresonanztomographie
- 1 February 2004
- Published by Springer Nature in Der Nervenarzt
- Vol. 75 (2) , 128-134
Differenzierung atypischer Parkinson-Syndrome und ihre Abgrenzung vom idiopathischen Parkinson-Syndrom mit Hilfe der Routine-Magnetresonanztomographie
- 1 February 2004
- Published by Springer Nature in Journal of Neurology
- Vol. 251 (1) , i39-i40
Botulinum toxin in rare pain syndromes
- 1 February 2004
- Published by Springer Nature in Journal of Neurology
- Vol. 251 (1) , i39-i40
Botulinum toxin in rare pain syndromes
- 1 October 2003
- Published by Springer Nature in Clinical Autonomic Research
- Vol. 13 (5) , 337-338
Botulism type B presenting as pure autonomic dysfunction
Botulism nowadays is a rare mostly food-borne disease caused by the toxin of Clostridium botulinum. On the other hand, botulinum toxin blocking cholinergic transmission has become a most powerful treatment option for many focal movement disorders and is increasingly used to treat autonomic disorders [2, 7, 8]. Although muscle weakness is the hallmark of botulism, autonomic dysfunction may be the leading clinical symptom in rare cases and should be included in the differential diagnosis of pure dysautonomia. Here, we describe a patient with autonomic dysfunction as the leading symptom of botulism type B.
- 1 October 2003
- Published by Springer Nature in Clinical Autonomic Research
- Vol. 13 (5) , 337-338
Botulism type B presenting as pure autonomic dysfunction
Botulism nowadays is a rare mostly food-borne disease caused by the toxin of Clostridium botulinum. On the other hand, botulinum toxin blocking cholinergic transmission has become a most powerful treatment option for many focal movement disorders and is increasingly used to treat autonomic disorders [2, 7, 8]. Although muscle weakness is the hallmark of botulism, autonomic dysfunction may be the leading clinical symptom in rare cases and should be included in the differential diagnosis of pure dysautonomia. Here, we describe a patient with autonomic dysfunction as the leading symptom of botulism type B.
- Open Access
- 1 June 2003
- Published by American Medical Association (AMA) in Archives of Dermatology
- Vol. 139 (6) , 731-736
Botulinum Toxin Type A Is a Safe and Effective Treatment for Axillary Hyperhidrosis Over 16 Months
Research from JAMA Dermatology — Botulinum Toxin Type A Is a Safe and Effective Treatment for Axillary Hyperhidrosis Over 16 Months — A Prospective Study
- 1 June 2003
- Published by American Medical Association (AMA) in Archives of Dermatology
- Vol. 139 (6) , 731-736
Open AccessBotulinum Toxin Type A Is a Safe and Effective Treatment for Axillary Hyperhidrosis Over 16 Months
Research from JAMA Dermatology — Botulinum Toxin Type A Is a Safe and Effective Treatment for Axillary Hyperhidrosis Over 16 Months — A Prospective Study
- Open Access
- 1 March 2002
- Published by Oxford University Press (OUP) in British Journal of Surgery
- Vol. 89 (3) , 259-261
Treatment of axillary hyperhidrosis
- 1 March 2002
- Published by Oxford University Press (OUP) in British Journal of Surgery
- Vol. 89 (3) , 259-261
Open AccessTreatment of axillary hyperhidrosis
- 1 January 2002
- Published by Springer Nature in Journal of Neurology
- Vol. 249 (1) , 57-63
A randomized, double-masked, crossover comparison of the efficacy and safety of botulinum toxin type A produced from the original bulk toxin source and current bulk toxin source for the treatment of cervical dystonia
In 1997, the US FDA approved a new bulk toxin source (now referred to as current) for the manufacture of botulinum toxin type A (BTX-A). The current BTX-A preparation has a lower neurotoxin complex protein load than the original BTX-A preparation, which may reduce antigenic potential. The present double-masked, multicenter study compared the efficacy and safety of BTX-A (BOTOX®) produced from both original and current bulk toxin sources for the treatment of cervical dystonia. Patients (N=133) were injected with BTX-A produced from original and current bulk toxin sources using a crossover design. Adverse events were assessed at each visit. Efficacy was assessed at 2 and 6 weeks post-injection using the severity and pain-disability subscales of the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS). Mean BTX-A doses were comparable (original: 155 U, current: 156 U). Both BTX-A preparations produced similar, statistically significant reductions in TWSTRS severity and pain-disability scores at weeks 2 and 6 post-injection. The original and current BTX-A preparations showed no significant differences in adverse events, including both treatment-related (34 %, 31 %) and treatment-unrelated (27 %, 32 %), respectively. BTX-A produced from the original and current bulk toxin sources showed comparable efficacy and safety in the treatment of cervical dystonia; both significantly reduced dystonia severity and pain.
- 1 January 2002
- Published by Springer Nature in Journal of Neurology
- Vol. 249 (1) , 57-63
A randomized, double-masked, crossover comparison of the efficacy and safety of botulinum toxin type A produced from the original bulk toxin source and current bulk toxin source for the treatment of cervical dystonia
In 1997, the US FDA approved a new bulk toxin source (now referred to as current) for the manufacture of botulinum toxin type A (BTX-A). The current BTX-A preparation has a lower neurotoxin complex protein load than the original BTX-A preparation, which may reduce antigenic potential. The present double-masked, multicenter study compared the efficacy and safety of BTX-A (BOTOX®) produced from both original and current bulk toxin sources for the treatment of cervical dystonia. Patients (N=133) were injected with BTX-A produced from original and current bulk toxin sources using a crossover design. Adverse events were assessed at each visit. Efficacy was assessed at 2 and 6 weeks post-injection using the severity and pain-disability subscales of the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS). Mean BTX-A doses were comparable (original: 155 U, current: 156 U). Both BTX-A preparations produced similar, statistically significant reductions in TWSTRS severity and pain-disability scores at weeks 2 and 6 post-injection. The original and current BTX-A preparations showed no significant differences in adverse events, including both treatment-related (34 %, 31 %) and treatment-unrelated (27 %, 32 %), respectively. BTX-A produced from the original and current bulk toxin sources showed comparable efficacy and safety in the treatment of cervical dystonia; both significantly reduced dystonia severity and pain.
- 10 April 2001
- Published by Springer Nature in Journal of Neurology
- Vol. 248 (S1) , I31-I33
Evidence-based medicine: botulinum toxin in focal hyperhidrosis
All studies performed so far indicate that BTX-A is a safe and effective treatment for focal hyperhidrosis of the axillae and palms, for gustatory sweating, and for some other rare conditions associated with focal hyperhidrosis. Based on two large well-designed, double-blind, placebo-controlled study there is class 1 evidence for the efficacy of BTX-A in axillary hyperhidrosis, and class 2 evidence for BTX-A in gustatory and palmar sweating (classification according to the Quality Standards Subcommittee of the American Academy of Neurology, 1994). Other indications (forehead sweating, plantar hyperhidrosis, truncal sweating) are only anecdotally reported.
- 10 April 2001
- Published by Springer Nature in Journal of Neurology
- Vol. 248 (S1) , I31-I33
Evidence-based medicine: botulinum toxin in focal hyperhidrosis
All studies performed so far indicate that BTX-A is a safe and effective treatment for focal hyperhidrosis of the axillae and palms, for gustatory sweating, and for some other rare conditions associated with focal hyperhidrosis. Based on two large well-designed, double-blind, placebo-controlled study there is class 1 evidence for the efficacy of BTX-A in axillary hyperhidrosis, and class 2 evidence for BTX-A in gustatory and palmar sweating (classification according to the Quality Standards Subcommittee of the American Academy of Neurology, 1994). Other indications (forehead sweating, plantar hyperhidrosis, truncal sweating) are only anecdotally reported.